{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006163","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.756539+00:00","generated_at":"2026-06-06T03:09:03.941487+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MyMD Pharmaceuticals effectuates 1-for-30 reverse stock split to maintain Nasdaq listing","bullets":["Reverse stock split at 1-for-30 ratio effective Feb 14, 2024 at 4:05 p.m. EST.","Outstanding shares reduced from ~62.7M to ~2.09M; authorized shares reduced from 500M to 16.67M.","Common stock begins trading on split-adjusted basis Feb 15 under same ticker MYMD; new CUSIP 62856X201.","Fractional shares rounded up to nearest whole share; proportional adjustments to warrants, preferred stock, and equity awards.","Company states split is intended to maintain compliance with Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006163","json":"https://secwatch.observer/filing/0001493152-24-006163.json","markdown":"https://secwatch.observer/filing/0001493152-24-006163.md","text":"https://secwatch.observer/filing/0001493152-24-006163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224006163/0001493152-24-006163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224006163/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:09:03.941487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b80554235c073817ee6c6a1e498600e859f4b4b","claim":"Q/C TECHNOLOGIES, INC.: Certificate of Amendment filed to effect a 1-for-30 reverse stock split and reduce authorized shares from 500 million to 16,666,666 (effective 2024-02-14).","evidence_excerpt":"On February 13, 2024, MyMD Pharmaceuticals, Inc. (the \" Company \") announced that it had filed with the Secretary of State of the State of New Jersey a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the \" Charter Amendment \") to effect a 1-for-30 reverse stock split (the \" Reverse Stock Split \") of the Company’s common stock, without par value (the \" Common Stock \"), effective as of 4:05 p.m. Eastern Standard Time on February 14, 2024 (the \" Effective Time \").","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224006163/0001493152-24-006163-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}